<DOC>
	<DOCNO>NCT00003857</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen tumor cell . It yet know radiation therapy effective observation , without tamoxifen , treat ductal carcinoma situ . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy observation , without tamoxifen , treat woman ductal carcinoma situ .</brief_summary>
	<brief_title>Radiation Therapy With Without Optional Tamoxifen Treating Women With Ductal Carcinoma Situ</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy whole breast radiotherapy v observation without optional tamoxifen decrease delay appearance local failure ( invasive situ ) prevent need mastectomy woman good-risk ductal carcinoma situ ( DCIS ) breast . - Compare distant disease-free survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 50 vs 50 ) , final path margin ( negative v 3-9 mm v least 10 mm ) , mammographic size primary ( great 1 cm v great 1 cm 2.5 cm ) , nuclei grade ( low v intermediate ) , tamoxifen use ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients undergo observation may receive optional oral tamoxifen daily ( discretion physician ) 5 year . - Arm II : Beginning within 12 week final surgery , patient receive radiotherapy whole breast daily , 5 day week , 3.5-5.5 week . Patients may receive optional tamoxifen arm I . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 1,790 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Ductal carcinoma situ ( DCIS ) breast detect mammogram time diagnosis Unicentric Lesions ≤ 2.5 cm Low nuclei grade ( NG1 ) intermediate nuclei grade ( NG2 ) necrosis &lt; one third involved duct Inked margin ≥ 3 mm Clinically node negative Nonpalpable No suspicious area postoperative mammogram take within 12 week final surgery No bloody nipple discharge No 12 week since prior final surgery ( arm II ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 26 Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing No active connective tissue disorder ( e.g. , lupus scleroderma ) No prior malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : No concurrent hormonal therapy ( e.g. , raloxifene , hormone replacement therapy , birth control pill ) Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>26 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>breast cancer situ</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
</DOC>